Report Overview

Australia Regenerative Medicine Market - Industry Trends & Forecast Report, 2029

Australia regenerative medicine market size was estimated at USD 0.3 billion in 2022. During the forecast period between 2023 and 2029, the size of Australia regenerative medicine market is projected to grow at a CAGR of 25.06% reaching a value of USD 1.4 billion by 2029. Major growth drivers for the Australia regenerative medicine market include an increasing healthcare facilities and progress in the pharmaceutical industry. Rising research and development activities to enhance pharmaceutical products and discover curative therapies for unknown diseases are also contributing to the market's expansion. Regenerative medicines, which continually undergo research and development, aim to improve healthcare and patient care services. Biomedical techniques such as cell therapy, immunomodulation therapy, and tissue engineering are gaining prominence, further fueling the market's growth. Increased investments in biomedical procedures and research are expected to propel the market in the next five years, with a USD 60 million grant from the Australia Department of Industry, Innovation, and Science supporting the development of integrated cell therapies. The rising prevalence of chronic neurological diseases and cancers, alongside the growing geriatric population prone to various disorders, will drive demand for regenerative medicine during the forecast period, making it a promising sector for healthcare advancements.

Australia Regenerative Medicine Market – Overview

The Australia regenerative medicine market refers to the sector within the Australian healthcare industry that focuses on the development, production, and utilization of advanced medical therapies aimed at harnessing the body's natural regenerative capabilities. These therapies often involve innovative approaches such as cell therapy, gene therapy, tissue engineering, and other biomedical techniques to repair, replace, or regenerate damaged or diseased tissues and organs. The market's primary objective is to provide more effective and personalized treatments for a wide range of medical conditions, including chronic diseases, injuries, and degenerative disorders. As a growing field of medical science, the Australia regenerative medicine market holds promising potential for revolutionizing healthcare and improving patient outcomes in the country.

Australia Regenerative Medicine Market

Growth Drivers

Increasing Prevalence of Chronic Diseases and Injuries

With a rising number of individuals affected by these conditions, there is a growing demand for advanced medical treatments and therapies that can effectively address and manage these health challenges. Regenerative medicine, with its innovative approaches like cell therapy, gene therapy, and tissue engineering, offers promising solutions for treating chronic diseases and injuries. As a result, the market is experiencing a boost as healthcare providers and patients recognize the potential benefits of these advanced therapies in improving patient outcomes and enhancing overall healthcare services.

Restraints

High Cost of Regenerative Medicines

The Australia regenerative medicine market faces a significant constraint due to the high cost of regenerative medicine treatments. The expenses associated with these advanced therapies pose challenges in terms of accessibility and affordability for patients, limiting the widespread adoption of regenerative medicine treatments in the country. As a result, efforts to address the cost barrier and make regenerative medicine more economically viable are crucial to unlock the full potential of this innovative field and foster its growth in Australia.

Impact of COVID-19 on Australia Regenerative Medicine Market

COVID-19 pandemic had a mixed impact on the Australia regenerative medicine market. Initially, disruptions to healthcare services and supply chains affected research and development activities. However, the pandemic also brought attention to the importance of advanced medical solutions, and regenerative medicine's potential to address COVID-19-related complications and accelerate patient recovery gained recognition. Additionally, the pandemic underscored the significance of personalized and minimally invasive treatments, driving demand for regenerative medicine. Financial constraints and uncertainties hindered investment and delayed some projects during the pandemic. As the situation evolved, the market adapted to the challenges and opportunities, positioning itself for further growth in the post-pandemic era.

Australia Regenerative Medicine Market

Segmental Coverage

Australia Regenerative Medicine Market – By Therapy Type

By therapy type, the Australia regenerative medicine market is divided into Cell Therapy, Stem Cell Therapy, Tissue Engineering, and Gene Therapy. The cell therapy segment is expected hold the highest share in the Australia regenerative medicine market during the forecast period, due to its potential in addressing a wide range of medical conditions. Cell therapy involves using living cells to restore or regenerate damaged tissues and organs, offering personalized and targeted treatment solutions. Its success in treating chronic diseases, injuries, and degenerative disorders has garnered significant attention from both healthcare providers and patients. Moreover, ongoing research and advancements in this field have further boosted its popularity. As a result, the cell therapy segment remains at the forefront of the regenerative medicine market, driving its overall growth in Australia. Also, cell therapy includes autologous cell therapy and allogenic cell therapy.

Australia Regenerative Medicine Market – By Application

By application, the Australia regenerative medicine market is divided into Wound Care, Musculoskeletal, Oncology, Dental, and Duchenne Muscular Dystrophy segments. The musculoskeletal segment holds the highest share in the Australia regenerative medicine market by application due to the prevalence of musculoskeletal disorders in the country. These conditions, including osteoarthritis, joint injuries, and bone fractures, affect a significant portion of the population, leading to a strong demand for effective treatments. Regenerative medicine, particularly cell therapy and tissue engineering, has shown promising results in repairing and regenerating musculoskeletal tissues, providing patients with improved mobility and pain relief. The success of these therapies in addressing musculoskeletal issues has contributed to the segment's dominance in the market, making it the preferred choice for healthcare providers and patients seeking innovative solutions for such conditions.

Competitive Landscape

Major players operating in the Australia regenerative medicine market include Mesoblast Limited, Cynata Therapeutics Limited, Orthocell Limited, Healius Limited, Capricor Therapeutics Limited, Progenitor Cell Therapy Limited, Cellmid Limited, Avita Medical Limited, Mesoblast USA, Inc., and Cynata Therapeutics Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Scope of the Report

By Therapy Type

• Cell Therapy

• Stem Cell Therapy

• Tissue-engineering

• Gene Therapy

By Application

• Wound Care

• Musculoskeletal

• Oncology

• Dental

• DMD (Duchenne Muscular Dystrophy)

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. Australia Regenerative Medicine Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Increasing prevalence of chronic diseases and injuries
         2. Growing demand for minimally invasive and personalized treatments
         3. Advances in cell therapy, gene therapy, and tissue engineering
      2. Restrains
         1. High cost of regenerative medicine treatments
         2. Lack of regulatory approval for some regenerative medicine products
      3. Opportunities
         1. Development of new regenerative medicine products for a wider range of diseases and conditions
         2. Increased adoption of regenerative medicine by healthcare providers
      4. Challenges
         1. Need to develop more cost-effective regenerative medicine treatments
         2. Need to address ethical concerns about the use of stem cells
   3. Technological Advancements/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. Australia Regenerative Medicine Market Overview
   1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Therapy Type
         1. Cell Therapy
            1. Autologous Cell Therapy
            2. Allogenic Cell Therapy
         2. Stem Cell Therapy
            1. Allogeneic Stem Cell Therapy
            2. Autologous Stem Cell Therapy
         3. Tissue-engineering
         4. Gene Therapy
         5. Others
      2. By Application
         1. Wound Care
         2. Musculoskeletal
         3. Oncology
         4. Dental
         5. DMD (Duchenne Muscular Dystrophy)
         6. Others
5. Competitive Landscape
   1. List of Key Players and Their Offerings
   2. Australia Regenerative Medicine Company Market Share Analysis, 2022
   3. Competitive Benchmarking, By Operating Parameters
   4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
6. Impact of Covid–19 on Australia Regenerative Medicine Market
7. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
   1. Mesoblast Limited
   2. Cynata Therapeutics Limited
   3. Orthocell Limited
   4. Healius Limited
   5. Capricor Therapeutics Limited
   6. Progenitor Cell Therapy Limited
   7. Cellmid Limited
   8. Avita Medical Limited
   9. Mesoblast USA, Inc.
   10. Cynata Therapeutics Inc.
   11. Other Prominent Players
8. Key Strategic Recommendations
9. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3.  Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
   4.  Breakdown of Primary Research Respondents, By Region
   5.  Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.

List of Figures

Figure 1       Australia Regenerative Medicine Segmentation      

Figure 2       Australia Regenerative Medicine Market Value Chain Analysis     

Figure 3       Company Market Share Analysis, 2022

Figure 4       Australia Regenerative Medicine Market Size, By Value (USD Million), 2019–2029         

Figure 5       Australia Regenerative Medicine Market Share, By Therapy Type, By Value, 2019–2029 

Figure 6       Australia Regenerative Medicine Market Share, By Application, By Value, 2019–2029 

List of Tables

Table 1        Australia Regenerative Medicine Market Size, By Value (USD Million), 2019–2029

Table 2        Australia Regenerative Medicine Market Size, By Therapy Type, By Value, 2019–2029

Table 3        Australia Regenerative Medicine Market Size, By Application, By Value, 2019–2029

Table 4        Mesoblast Limited Company Overview

Table 5        Mesoblast Limited Financial Overview

Table 6        Cynata Therapeutics Limited Company Overview

Table 7        Cynata Therapeutics Limited Financial Overview

Table 8        Orthocell Limited Company Overview

Table 9        Orthocell Limited Financial Overview

Table 10      Healius Limited Company Overview

Table 11      Healius Limited Financial Overview

Table 12      Capricor Therapeutics Limited Company Overview

Table 13      Capricor Therapeutics Limited Financial Overview

Table 14      Progenitor Cell Therapy Limited Company Overview

Table 15      Progenitor Cell Therapy Limited Financial Overview

Table 16      Cellmid Limited Company Overview

Table 17      Cellmid Limited Financial Overview

Table 18      Avita Medical Limited Company Overview

Table 19      Avita Medical Limited Financial Overview

Table 20      Mesoblast USA, Inc. Company Overview

Table 21      Mesoblast USA, Inc. Financial Overview

Table 22      Cynata Therapeutics Inc. Company Overview

Table 23      Cynata Therapeutics Inc. Financial Overview

Table 24      Other Prominent Players Company Overview

Table 25      Other Prominent Players Financial Overview